DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

January 31, 2016

Conditions
Hepatitis C, Chronic
Interventions
DRUG

TPV/PEG-IFN/RBV

"Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.~Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg).~Drug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly."

Trial Locations (2)

2010

St Vincent's Hospital, Sydney

5000

Royal Adelaide Hospital, Adelaide

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Janssen-Cilag Ltd.

INDUSTRY

lead

Kirby Institute

OTHER_GOV